Last reviewed · How we verify
Dolutegravir dispersible tablet
At a glance
| Generic name | Dolutegravir dispersible tablet |
|---|---|
| Sponsor | ViiV Healthcare |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- UNIVERSAL 1: Pharmacokinetic Study of a Novel DTG/FTC/TAF Dose Ratio for Children (PHASE2)
- DTG/3TC Fixed Dose Formulations for the Maintenance of Virological Suppression in Children With HIV Infection Aged 2 to <15 Years Old (PHASE2, PHASE3)
- Dolutegravir Study in HIV-1 Participants Completing IMPAACT Studies P1093 and P2019 (PHASE3)
- A Study of Daily Rifapentine Combined With Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age With and Without HIV (PHASE1, PHASE2)
- A Study of the Safety, Tolerability, and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1 (PHASE1)
- Safety of and Immune Response to Dolutegravir in HIV-1 Infected Infants, Children, and Adolescents (PHASE1, PHASE2)
- Pharmacokinetics and Safety of DolutegravIr in Neonate (PHASE1, PHASE2)
- Relative Bioavailability Study to Investigate a Potential Interaction Between DTG DT and F/TAF TOS. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dolutegravir dispersible tablet CI brief — competitive landscape report
- Dolutegravir dispersible tablet updates RSS · CI watch RSS
- ViiV Healthcare portfolio CI